CD70 and acute myeloid leukemia: So far, cusatuzumab is being evaluated in patients with acute myeloid leukemia (AML) in multiple clinical trials (NCT04023526 and NCT04150887), and has shown a potent killing efficacy to CD70 + leukemia stem cells with manageable adverse events42.